EGFR and colorectal cancer: Russo et al. examined human colorectal cancer (CRC) cells treated with EGFR antibodies or BRAF inhibitors and found that that drug-tolerant persister cells downregulate mismatch repair (MMR) and homologous recombination (HR) DNA repair genes, whereas error-prone polymerases are upregulated [124].